Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

2021 Cover

Stanton Mehr February 12, 2021February 12, 2021

Published by Stanton Mehr

View all posts by Stanton Mehr

Published February 12, 2021February 12, 2021

Post navigation

Previous Post 2021 Cover

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

CVS Caremark’s Formulary Changes: Eye Pain for Eylea November 28, 2023
When Will a Biosimilar Version of Xolair® be Available? November 17, 2023
A Busy Month for Biosimilar Adalimumab Product Updates November 8, 2023
First Biosimilar Interleukin Approved by the FDA: Amgen Wezlana™ Is Interchangeable with Stelara® November 1, 2023
Update on Coherus’ Quest for Neulasta OnPro® Competitor October 30, 2023
Celltrion Scores FDA Approval of SC Infliximab: Will Use of the IV Formulation Be Affected? October 24, 2023
A Biosimilar Mainstay Faces an ASP Cliff October 12, 2023
The Push and Pull of Buy and Bill for Biosimilars on the Medical Benefit October 9, 2023
Biosimilars, Generics, and the Sustainability Nexus October 6, 2023
The First Biosimilar for Actemra® is Approved by FDA October 2, 2023

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

CVS Caremark’s Formulary Changes: Eye Pain for Eylea
Biosimilar Approval Status
Twelve Potential Competitors and Counting: An Update of the Denosumab Biosimilar Pipeline
The Evolution of the Biosimilars Market
When Will a Biosimilar Version of Xolair® be Available?
The Adalimumab Biosimilar Great Wave Launches, and WAC Pricing Covers the Spectrum
A Busy Month for Biosimilar Adalimumab Product Updates
The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
Update on Coherus’ Quest for Neulasta OnPro® Competitor
Fylnetra

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.